Elevated fecal M2-pyruvate kinase in children with cystic fibrosis: A clue to the increased risk of intestinal malignancy in adulthood?

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 5, 2015, Pages 866-871

  Pang, Tamara ^a   Leach, Steven T ^a   Katz, Tamarah ^b   Jaffe, Adam ^a,b   Day, Andrew S ^c   Ooi, Chee Y ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Biological markers; Cystic fibrosis; Inflammation; Intestinal neoplasms; Pyruvate kinase

Indexed keywords

CALGRANULIN; PYRUVATE KINASE; BIOLOGICAL MARKER;

ADULT; ADULTHOOD; ARTICLE; CANCER RISK; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; ENTERITIS; FECES ANALYSIS; FEMALE; HUMAN; INTESTINE CANCER; MALE; PANCREAS INSUFFICIENCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TURNOVER TIME; ADOLESCENT; CHEMISTRY; COLONIC NEOPLASMS; COMPLICATION; ENZYMOLOGY; FECES; INFANT; INFLAMMATION; INTESTINAL DISEASES; INTESTINE; PATHOLOGY; PRESCHOOL CHILD; RISK;

ADOLESCENT; BIOMARKERS; CHILD; CHILD, PRESCHOOL; COLONIC NEOPLASMS; CYSTIC FIBROSIS; FECES; FEMALE; HUMANS; INFANT; INFLAMMATION; INTESTINAL DISEASES; INTESTINES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; PROSPECTIVE STUDIES; PYRUVATE KINASE; RISK;

EID: 84926688564     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12842     Document Type: Article

References (36)

1. Riordan JR, Rommens JM, Kerem B etal. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-1073.
2. Rommens JM, Iannuzzi MC, Kerem B etal. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245: 1059-1065.
3. Buzzetti R, Salvatore D, Baldo E etal. An overview of international literature from cystic fibrosis registries: 1. Mortality and survival studies in cystic fibrosis. J. Cyst. Fibros. 2009; 8: 229-237.
4. Cystic Fibrosis Canada. The Canadian Cystic Fibrosis Registry: 2012 Annual Report. Canada: Cystic Fibrosis Canada, 2014.
5. Neglia JP, FitzSimmons SC, Maisonneuve P etal. The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N. Engl. J. Med. 1995; 332: 494-499.
6. Maisonneuve P, FitzSimmons SC, Neglia JP etal. Cancer risk in nontransplanted and transplanted cystic fibrosis patients: a 10-year study. J. Natl Cancer Inst. 2003; 95: 381-387.
7. Maisonneuve P, Marshall BC, Knapp EA etal. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. J. Natl Cancer Inst. 2013; 105: 122-129.
8. Gallagher AM, Gottlieb RA. Proliferation, not apoptosis, alters epithelial cell migration in small intestine of CFTR null mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2001; 281: G681-687.
9. Gottlieb RA, Dosanjh A. Mutant cystic fibrosis transmembrane conductance regulator inhibits acidification and apoptosis in C127 cells: possible relevance to cystic fibrosis. Proc. Natl. Acad. Sci. U S A 1996; 93: 3587-3591.
10. Mehta A. Cystic fibrosis as a bowel cancer syndrome and the potential role of CK2. Mol. Cell. Biochem. 2008; 316: 169-175.
11. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2004; 287: G7-17.
12. Kerbiriou M, Teng L, Benz N etal. The calpain, caspase 12, caspase 3 cascade leading to apoptosis is altered in F508del-CFTR expressing cells. PLoS One 2009; 4: e8436.
13. Munkholm P, Langholz E, Davidsen M etal. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993; 105: 1716-1723.
14. Ekbom A, Helmick C, Zack M etal. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med. 1990; 323: 1228-1233.
15. Velayos FS, Loftus EV Jr, Jess T etal. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006; 130: 1941-1949.
16. Norkina O, Kaur S, Ziemer D etal. Inflammation of the cystic fibrosis mouse small intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 2004; 286: G1032-1041.
17. Bruzzese E, Raia V, Gaudiello G etal. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol. Ther. 2004; 20: 813-819.
18. Smyth RL, Croft NM, O'Hea U etal. Intestinal inflammation in cystic fibrosis. Arch. Dis. Child. 2000; 82: 394-399.
19. Werlin SL, Benuri-Silbiger I, Kerem E etal. Evidence of intestinal inflammation in patients with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 2010; 51: 304-308.
20. Koss K, Maxton D, Jankowski JA. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. Colorectal Dis. 2008; 10: 244-248.
21. Chung-Faye G, Hayee B, Maestranzi S etal. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm. Bowel Dis. 2007; 13: 1374-1378.
22. Tonus C, Sellinger M, Koss K etal. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J. Gastroenterol. 2012; 18: 4004-4011.
23. Leach ST, Yang Z, Messina I etal. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand. J. Gastroenterol. 2007; 42: 1321-1331.
24. Nahidi L, Leach ST, Sidler MA etal. Osteoprotegerin in pediatric Crohn's disease and the effects of exclusive enteral nutrition. Inflamm. Bowel Dis. 2011; 17: 516-523.
25. Bjerke K, Halstensen TS, Jahnsen F etal. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993; 34: 1357-1363.
26. Dhaliwal J, Katz T, Leach S etal. Elucidating the mechanism of intestinal inflammation in CF: one step closer. Pediatr. Pulmonol. 2013; 47 (S36): 404.
27. Fagerberg UL, Loof L, Merzoug RD etal. Fecal calprotectin levels in healthy children studied with an improved assay. J. Pediatr. Gastroenterol. Nutr. 2003; 37: 468-472.
28. Czub E, Herzig KH, Szaflarska-Popawska A etal. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand. J. Gastroenterol. 2007; 42: 1147-1150.
29. Turner D, Leach ST, Mack D etal. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut 2010; 59: 1207-1212.
30. Arthur JC, Perez-Chanona E, Muhlbauer M etal. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012; 338: 120-123.
31. Velcich A, Yang W, Heyer J etal. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002; 295: 1726-1729.
32. Freedman SD, Katz MH, Parker EM etal. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc. Natl. Acad. Sci. U S A 1999; 96: 13995-14000.
33. Ooi CY, Dorfman R, Cipolli M etal. Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. Gastroenterology 2011; 140: 153-161.
34. Billings JL, Dunitz JM, McAllister S etal. Early colon screening of adult patients with cystic fibrosis reveals high incidence of adenomatous colon polyps. J. Clin. Gastroenterol. 2014; 48: e85-88.
35. Pezzilli R, Barassi A, Morselli-Labate AM etal. Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation. J. Gastroenterol. 2007; 42: 754-760.
36. Aloysius MM, Zaitoun AM, Bates TE etal. Complete absence of M2-pyruvate kinase expression in benign pancreatic ductal epithelium and pancreaticobiliary and duodenal neoplasia. BMC Cancer 2009; 15: 327.